Ratings MediPal Holdings Corporation

Equities

7459

JP3268950007

Delayed Japan Exchange Other stock markets 08:45:13 2024-04-18 pm EDT			5-day change	1st Jan Change
2,364 ^JPY	-0.90%		-1.28%	+3.26%

2023	Tranche Update on MediPal Holdings Corporation's Equity Buyback Plan announced on May 12, 2023.	CI
2023	MediPal Holdings Corporation's Equity Buyback announced on May 12, 2023 has closed with 4,171,900 shares, representing 1.97% for ¥9,999.86 million.	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MEDIPAL HOLDINGS CORPORATION	+3.26%	3.25B	C
MCKESSON CORPORATION	+12.06%	69.11B	C+
CARDINAL HEALTH, INC.	+5.16%	25.91B	C+
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+4.48%	8.01B	B
SINOPHARM GROUP CO. LTD.	-3.28%	7.91B	C
HUADONG MEDICINE CO., LTD	-23.97%	7.27B	B-
H. LUNDBECK A/S	-0.67%	4.51B	B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+20.68%	4.48B	B+
EBOS GROUP LIMITED	-4.23%	3.95B	B-
GALENICA AG	-3.99%	3.79B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes